By generating four IgG isotype-switch variants of the high affinity 34–3C anti-erythrocyte autoantibody, and comparing them to the IgG variants of the low affinity 4C8 anti-erythrocyte autoantibody that we have previously studied, we evaluated in this study how high affinity binding to erythrocytes influences the pathogenicity of each IgG isotype in relation to the respective contributions of Fcγ receptor (FcγR) and complement. The 34–3C autoantibody opsonizing extensively circulating erythrocytes efficiently activated complement in vivo (IgG2a = IgG2b > IgG3), except for the IgG1 isotype, while the 4C8 IgG autoantibody failed to activate complement. The pathogenicity of the 34–3C autoantibody of IgG2b and IgG3 isotypes was dramatically higher (>200-fold) than that of the corresponding isotypes of the 4C8 antibody. This enhanced activity was highly (IgG2b) or totally (IgG3) dependent on complement. In contrast, erythrocyte-binding affinities only played a minor role in in vivo hemolytic activities of the IgG1 and IgG2a isotypes of 34–3C and 4C8 antibodies, where complement was not or only partially involved, respectively. The remarkably different capacities of four different IgG isotypes of low and high affinity anti-erythrocyte autoantibodies to activate FcγR-bearing effector cells and complement in vivo demonstrate the role of autoantibody affinity maturation and of IgG isotype switching in autoantibody-mediated pathology.
Skip Nav Destination
Article navigation
18 March 2002
Article|
March 11 2002
Complement Activation Selectively Potentiates the Pathogenicity of the IgG2b and IgG3 Isotypes of a High Affinity Anti-Erythrocyte Autoantibody
Samareh Azeredo da Silveira,
Samareh Azeredo da Silveira
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Shuichi Kikuchi,
Shuichi Kikuchi
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Liliane Fossati-Jimack,
Liliane Fossati-Jimack
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Search for other works by this author on:
Thomas Moll,
Thomas Moll
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Takashi Saito,
Takashi Saito
3Department of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
Search for other works by this author on:
J. Sjef Verbeek,
J. Sjef Verbeek
4Department of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, Netherlands
Search for other works by this author on:
Marina Botto,
Marina Botto
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Search for other works by this author on:
Mark J. Walport,
Mark J. Walport
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Search for other works by this author on:
Michael Carroll,
Michael Carroll
5Center for Blood Research and Department of Pathology, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Shozo Izui
Shozo Izui
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Search for other works by this author on:
Samareh Azeredo da Silveira
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Shuichi Kikuchi
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Liliane Fossati-Jimack
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Thomas Moll
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Takashi Saito
3Department of Molecular Genetics, Chiba University Graduate School of Medicine, Chiba 260, Japan
J. Sjef Verbeek
4Department of Human and Clinical Genetics, Leiden University Medical Center, 2300 RA Leiden, Netherlands
Marina Botto
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Mark J. Walport
2Rheumatology Section, Hammersmith Campus, Imperial College School of Medicine, London W12 0NN, United Kingdom
Michael Carroll
5Center for Blood Research and Department of Pathology, Harvard Medical School, Boston, MA 02115
Shozo Izui
1Department of Pathology, University of Geneva, 1211 Geneva 4, Switzerland
Address correspondence to Dr. Shozo Izui, Department of Pathology, C.M.U., 1211 Geneva 4, Switzerland. Phone: 022-70-25-741; Fax: 022-70-25-746; E-mail: [email protected]
*
Abbreviations used in this paper: Ht, hematocrit; WT, wild-type.
Received:
December 06 2001
Revision Received:
January 10 2002
Accepted:
February 08 2002
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2002
J Exp Med (2002) 195 (6): 665–672.
Article history
Received:
December 06 2001
Revision Received:
January 10 2002
Accepted:
February 08 2002
Citation
Samareh Azeredo da Silveira, Shuichi Kikuchi, Liliane Fossati-Jimack, Thomas Moll, Takashi Saito, J. Sjef Verbeek, Marina Botto, Mark J. Walport, Michael Carroll, Shozo Izui; Complement Activation Selectively Potentiates the Pathogenicity of the IgG2b and IgG3 Isotypes of a High Affinity Anti-Erythrocyte Autoantibody . J Exp Med 18 March 2002; 195 (6): 665–672. doi: https://doi.org/10.1084/jem.20012024
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement